Free Trial
NASDAQ:EGRX

Eagle Pharmaceuticals (EGRX) Stock Price, News & Analysis

Eagle Pharmaceuticals logo
$3.09 -0.10 (-3.13%)
As of 08/28/2025 12:50 PM Eastern

About Eagle Pharmaceuticals Stock (NASDAQ:EGRX)

Key Stats

Today's Range
$2.55
$3.19
50-Day Range
$2.36
$3.75
52-Week Range
$1.50
$3.87
Volume
934 shs
Average Volume
6,682 shs
Market Capitalization
$40.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Eagle Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
34th Percentile Overall Score

EGRX MarketRank™: 

Eagle Pharmaceuticals scored higher than 34% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Eagle Pharmaceuticals.

    • Percentage of Shares Shorted

      0.46% of the float of Eagle Pharmaceuticals has been sold short.
    • Short Interest Ratio / Days to Cover

      Eagle Pharmaceuticals has a short interest ratio ("days to cover") of 60.3, which indicates bearish sentiment.
    • Change versus previous month

      Short interest in Eagle Pharmaceuticals has recently decreased by 1.40%, indicating that investor sentiment is improving.
    • Dividend Yield

      Eagle Pharmaceuticals does not currently pay a dividend.

    • Dividend Growth

      Eagle Pharmaceuticals does not have a long track record of dividend growth.

    • Percentage of Shares Shorted

      0.46% of the float of Eagle Pharmaceuticals has been sold short.
    • Short Interest Ratio / Days to Cover

      Eagle Pharmaceuticals has a short interest ratio ("days to cover") of 60.3, which indicates bearish sentiment.
    • Change versus previous month

      Short interest in Eagle Pharmaceuticals has recently decreased by 1.40%, indicating that investor sentiment is improving.
    • News Coverage This Week

      MarketBeat has tracked 1 news article for Eagle Pharmaceuticals this week, compared to 0 articles on an average week.
    • Insider Buying vs. Insider Selling

      In the past three months, Eagle Pharmaceuticals insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      28.90% of the stock of Eagle Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

    • Percentage Held by Institutions

      85.36% of the stock of Eagle Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

    • Read more about Eagle Pharmaceuticals' insider trading history.
    Receive EGRX Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Eagle Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

    By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

    EGRX Stock News Headlines

    Eagle Pharmaceuticals Announces 2025 Annual Meeting Date
    BONUS GUIDE - Ben Stein Prepares For the Next Financial Crisis
    With inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist Ben Stein—drawing on insights from his own experience and his father’s time advising two U.S. presidents—just released a new report on how to help protect your retirement from the next major crisis.tc pixel
    Eagle Pharmaceuticals, Inc. (EGRX) - Yahoo Finance
    EGRX Eagle Pharmaceuticals, Inc. - Seeking Alpha
    See More Headlines

    EGRX Stock Analysis - Frequently Asked Questions

    Eagle Pharmaceuticals' stock was trading at $0.50 at the start of the year. Since then, EGRX stock has increased by 518.0% and is now trading at $3.09.

    Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) released its quarterly earnings data on Tuesday, November, 9th. The specialty pharmaceutical company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $1.00. The specialty pharmaceutical company earned $39.85 million during the quarter, compared to the consensus estimate of $46.70 million.

    Shares of EGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Eagle Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Netflix (NFLX), Exxon Mobil (XOM), Advanced Micro Devices (AMD) and JPMorgan Chase & Co. (JPM).

    Company Calendar

    Last Earnings
    11/09/2021
    Today
    8/28/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    Pharmaceutical preparations
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:EGRX
    CIK
    827871
    Fax
    N/A
    Employees
    100
    Year Founded
    2007

    Profitability

    EPS (Trailing Twelve Months)
    N/A
    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    N/A
    Net Margins
    N/A
    Pretax Margin
    N/A
    Return on Equity
    N/A
    Return on Assets
    N/A

    Debt

    Debt-to-Equity Ratio
    N/A
    Current Ratio
    N/A
    Quick Ratio
    N/A

    Sales & Book Value

    Annual Sales
    $257.55 million
    Price / Sales
    0.16
    Cash Flow
    $7.73 per share
    Price / Cash Flow
    0.40
    Book Value
    N/A
    Price / Book
    N/A

    Miscellaneous

    Outstanding Shares
    12,987,000
    Free Float
    9,234,000
    Market Cap
    $40.13 million
    Optionable
    No Data
    Beta
    0.83

    Social Links

    Elon Musk's Next Move Cover

    Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

    Get This Free Report

    This page (NASDAQ:EGRX) was last updated on 8/29/2025 by MarketBeat.com Staff
    From Our Partners